Hideyuki Tominaga

3.8k total citations · 2 hit papers
45 papers, 3.1k citations indexed

About

Hideyuki Tominaga is a scholar working on Molecular Biology, Biochemistry and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Hideyuki Tominaga has authored 45 papers receiving a total of 3.1k indexed citations (citations by other indexed papers that have themselves been cited), including 27 papers in Molecular Biology, 27 papers in Biochemistry and 11 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Hideyuki Tominaga's work include Amino Acid Enzymes and Metabolism (27 papers), Epigenetics and DNA Methylation (19 papers) and Metabolism and Genetic Disorders (8 papers). Hideyuki Tominaga is often cited by papers focused on Amino Acid Enzymes and Metabolism (27 papers), Epigenetics and DNA Methylation (19 papers) and Metabolism and Genetic Disorders (8 papers). Hideyuki Tominaga collaborates with scholars based in Japan, China and United States. Hideyuki Tominaga's co-authors include Kazumi Sasamoto, Munetaka Ishiyama, Noboru Oriuchi, Masami Watanabe, Masanobu Shiga, Yosuke Ohkura, Yoshikatsu Kanai, Kyoichi Kaira, Shushi Nagamori and Tomoyuki Hamamoto and has published in prestigious journals such as Journal of Clinical Oncology, British Journal of Cancer and Journal of Pharmacology and Experimental Therapeutics.

In The Last Decade

Hideyuki Tominaga

45 papers receiving 3.1k citations

Hit Papers

2 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

A Combined Assay of Cell Viability and in Vitro Cytotoxicity with a Highly Water-Soluble Tetrazolium Salt, Neutral Red and Crystal Violet.

1996 645 citations Munetaka Ishiyama, Hideyuki Tominaga et al. Biological and Pharmaceutical Bulletin profile →
A water-soluble tetrazolium salt useful for colorimetric cell viability assay

1999 579 citations Hideyuki Tominaga, Munetaka Ishiyama et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Hideyuki Tominaga Japan	26	1.6k	940	594	491	416	45	3.1k
Sara Huerta‐Yépez Mexico	37	2.0k 1.2×	202 0.2×	811 1.4×	791 1.6×	213 0.5×	153	3.9k
Haiping Wang China	27	1.2k 0.7×	242 0.3×	556 0.9×	543 1.1×	82 0.2×	95	2.8k
Yangzom D. Bhutia United States	29	1.6k 1.0×	525 0.6×	536 0.9×	716 1.5×	43 0.1×	60	2.8k
Everett Stone United States	26	1.5k 0.9×	368 0.4×	261 0.4×	766 1.6×	60 0.1×	56	2.4k
David J. Yang United States	34	687 0.4×	207 0.2×	760 1.3×	592 1.2×	1.4k 3.3×	145	3.7k
Jan A. A. M. Kamps Netherlands	36	1.7k 1.1×	112 0.1×	332 0.6×	348 0.7×	208 0.5×	100	3.4k
Sumio Tanase Japan	35	1.7k 1.1×	468 0.5×	510 0.9×	112 0.2×	86 0.2×	91	3.2k
Dianwen Ju China	37	1.9k 1.2×	87 0.1×	539 0.9×	391 0.8×	162 0.4×	146	4.0k
José Luı́s Abad Spain	34	2.0k 1.3×	151 0.2×	224 0.4×	214 0.4×	232 0.6×	116	3.9k
Young Hee Ko United States	31	3.7k 2.3×	185 0.2×	663 1.1×	2.0k 4.1×	94 0.2×	69	5.1k

Countries citing papers authored by Hideyuki Tominaga

Since Specialization

Citations

This map shows the geographic impact of Hideyuki Tominaga's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hideyuki Tominaga with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hideyuki Tominaga more than expected).

Fields of papers citing papers by Hideyuki Tominaga

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hideyuki Tominaga. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hideyuki Tominaga. The network helps show where Hideyuki Tominaga may publish in the future.

Co-authorship network of co-authors of Hideyuki Tominaga

This figure shows the co-authorship network connecting the top 25 collaborators of Hideyuki Tominaga. A scholar is included among the top collaborators of Hideyuki Tominaga based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hideyuki Tominaga. Hideyuki Tominaga is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Jin, Chunhuan, Ling Wei, Ryuichi Ohgaki, et al.. (2020). Interaction of Halogenated Tyrosine/Phenylalanine Derivatives with Organic Anion Transporter 1 in the Renal Handling of Tumor Imaging Probes. Journal of Pharmacology and Experimental Therapeutics. 375(3). 451–462. 9 indexed citations

Nagamori, Shushi, Pattama Wiriyasermkul, Suguru Okuda, et al.. (2016). Structure–activity relations of leucine derivatives reveal critical moieties for cellular uptake and activation of mTORC1-mediated signaling. Amino Acids. 48(4). 1045–1058. 52 indexed citations

Kaira, Kyoichi, Tetsuya Higuchi, Noriaki Sunaga, et al.. (2016). Usefulness of 18F-α-Methyltyrosine PET for Therapeutic Monitoring of Patients with Advanced Lung Cancer. Anticancer Research. 36(12). 6481–6490. 9 indexed citations

Yamaguchi, Aiko, Hirofumi Hanaoka, Songji Zhao, et al.. (2015). Differentiation of malignant tumours from granulomas by using dynamic [18F]-fluoro-L-α-methyltyrosine positron emission tomography. EJNMMI Research. 5(1). 29–29. 5 indexed citations

Kaira, Kyoichi, Minoru Toyoda, Masato Shino, et al.. (2015). Expression of Amino Acid Transporters (LAT1 and ASCT2) in Patients with Stage III/IV Laryngeal Squamous Cell Carcinoma. Pathology & Oncology Research. 21(4). 1175–1181. 38 indexed citations

Shimizu, Kimihiro, Kyoichi Kaira, Yoshio Tomizawa, et al.. (2014). ASC amino-acid transporter 2 (ASCT2) as a novel prognostic marker in non-small cell lung cancer. British Journal of Cancer. 110(8). 2030–2039. 116 indexed citations

Paudyal, Bishnuhari, et al.. (2014). Detection of vascular endothelial growth factor in colon cancer xenografts using bevacizumab based near infrared fluorophore conjugate. Journal of Biomedical Science. 21(1). 35–35. 14 indexed citations

Kakizaki, Satoru, Kyoichi Kaira, Hiroki Tojima, et al.. (2014). Expression of amino acid transporters (LAT1, ASCT2 and xCT) as clinical significance in hepatocellular carcinoma. Hepatology Research. 45(9). 1014–1022. 52 indexed citations

Kaira, Kyoichi, Minoru Toyoda, Masato Shino, et al.. (2013). Clinicopathological Significance of L-type Amino Acid Transporter 1 (LAT1) Expression in Patients with Adenoid Cystic Carcinoma. Pathology & Oncology Research. 19(4). 649–656. 16 indexed citations

10.

Kaira, Kyoichi, Yutaka Sunose, Yasuhiro Ohshima, et al.. (2013). Clinical significance of L-type amino acid transporter 1 expression as a prognostic marker and potential of new targeting therapy in biliary tract cancer. BMC Cancer. 13(1). 482–482. 85 indexed citations

11.

Khunweeraphong, Narakorn, Shushi Nagamori, Pattama Wiriyasermkul, et al.. (2012). Establishment of Stable Cell Lines With High Expression of Heterodimers of Human 4F2hc and Human Amino Acid Transporter LAT1 or LAT2 and Delineation of Their Differential Interaction With ^|^alpha;-Alkyl Moieties. Journal of Pharmacological Sciences. 119(4). 368–380. 64 indexed citations

12.

Yoshioka, Hiroki, Shinji Yamamoto, Hirofumi Hanaoka, et al.. (2012). In vivo therapeutic effect of CDH3/P-cadherin-targeting radioimmunotherapy. Cancer Immunology Immunotherapy. 61(8). 1211–1220. 14 indexed citations

13.

Hanaoka, Hirofumi, Hiroki Yoshioka, Shinji Yamamoto, et al.. (2011). Predicting cetuximab accumulation in KRAS wild‐type and KRAS mutant colorectal cancer using ⁶⁴Cu‐labeled cetuximab positron emission tomography. Cancer Science. 103(3). 600–605. 30 indexed citations

14.

Ohshima, Yasuhiro, Hirofumi Hanaoka, Shigeki Watanabe, et al.. (2011). Preparation and biological evaluation of 3-[76Br]bromo-α-methyl-l-tyrosine, a novel tyrosine analog for positron emission tomography imaging of tumors. Nuclear Medicine and Biology. 38(6). 857–865. 11 indexed citations

15.

Paudyal, Bishnuhari, Hirofumi Hanaoka, Noboru Oriuchi, et al.. (2010). Imaging and biodistribution of Her2/neu expression in non‐small cell lung cancer xenografts with ⁶⁴Cu‐labeled trastuzumab PET. Cancer Science. 101(4). 1045–1050. 39 indexed citations

16.

Paudyal, Bishnuhari, et al.. (2010). Positron emission tomography imaging and biodistribution of vascular endothelial growth factor with ⁶⁴Cu‐labeled bevacizumab in colorectal cancer xenografts. Cancer Science. 102(1). 117–121. 54 indexed citations

17.

Hanaoka, Hirofumi, Hideyuki Tominaga, Keiichi Yamada, et al.. (2009). Evaluation of 64Cu-labeled DOTA-d-Phe1-Tyr3-octreotide (64Cu-DOTA-TOC) for imaging somatostatin receptor-expressing tumors. Annals of Nuclear Medicine. 23(6). 559–567. 19 indexed citations

18.

Kaira, Kyoichi, Noboru Oriuchi, Kimihiro Shimizu, et al.. (2009). ¹⁸F-FMT Uptake Seen Within Primary Cancer on PET Helps Predict Outcome of Non–Small Cell Lung Cancer. Journal of Nuclear Medicine. 50(11). 1770–1776. 45 indexed citations

19.

Tominaga, Hideyuki, Seiji Kodama, Naoki Matsuda, Keiji Suzuki, & Masami Watanabe. (2004). Involvement of Reactive Oxygen Species (ROS) in the Induction of Genetic Instability by Radiation. Journal of Radiation Research. 45(2). 181–188. 157 indexed citations

20.

Ishiyama, Munetaka, et al.. (1996). A Combined Assay of Cell Viability and in Vitro Cytotoxicity with a Highly Water-Soluble Tetrazolium Salt, Neutral Red and Crystal Violet.. Biological and Pharmaceutical Bulletin. 19(11). 1518–1520. 645 indexed citations breakdown →

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact